相关实验视频
Updated: Mar 3, 2026

07:37
Roux-en-Y Gastric Bypass Operation in Rats
Published on: June 11, 2012
24.4K
在RYGB中营养脆弱性被GLP-1疗法揭露
Juliana Madej1, Ernesto Robalino Gonzaga2, Mariam Naveed3
1Idaho College of Osteopathic Medicine, Meridian, ID.
ACG case reports journal
|March 2, 2026
概括
塞马格卢提德可以导致严重营养不良和肝损伤,在患者之前胃旁路手术. 对这些人来说,密切监测营养和肝功能至关重要.
科学领域:
- 胃肠病学 胃肠病学
- 内分泌学 在内分泌学.
- 腹部外科 腹部外科
背景情况:
- 葡萄糖类-1 (GLP-1) 受体激动剂越来越多地用于体重管理.
- 变化的胃肠道解剖学,如Roux-en-Y胃旁路术后,可能会影响药物吸收和新陈代谢.
研究的目的:
- 在Roux-en-Y胃绕道术后的患者中,在开始服用西马格卢提德后出现严重并发症的情况下报告.
- 突出GLP-1受体激活剂在患有腹手术史的患者中的潜在风险.
主要方法:
- 一个病人的病例报告,在开始服用西马格卢提德后出现营养不良和肝损伤.
- 对临床表现,管理和结果的审查.
主要成果:
- 患者经历了危及生命的营养不良,严重的微量营养素缺乏和急性肝损伤.
- 治疗需要重症监护,肠外营养和内镜旁路逆转.
结论:
- GLP-1受体激动剂可能会在患有胃肠道解剖学变化的患者中构成"双击"风险.
- 紧密监测营养状况和肝功能对于接受GLP-1治疗的腹痛后患者至关重要.
- 需要进一步研究安全的处方和管理策略.
相关概念视频
Glucagon-like Receptor Agonists
1.1K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.1K
Enteral Nutrition II: Nasointestinal and Gastrostomy Feeding
1.3K
Enteral nutrition encompasses various methods of delivering nutrition directly to the gastrointestinal (GI) tract, bypassing traditional oral intake. It is particularly beneficial for patients who cannot eat by mouth but have a functioning digestive system. Key methods include nasointestinal feeding, gastrostomy, and jejunostomy, each suited to different clinical scenarios based on the patient's needs and condition.
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
Nasointestinal Feeding
Nasointestinal feeding involves placing a tube...
1.3K
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution
326
Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
326
Gastric Emptying
4.3K
Gastric emptying occurs when the stomach gradually releases chyme into the duodenum. When the stomach is distended, it triggers the release of gastrin, a hormone that promotes gastric acid secretion to aid in digestion. Additionally, stomach distension contributes to peristaltic waves that propel gastric contents toward the pyloric region. The gastroenteric reflex, on the other hand, primarily stimulates peristalsis in the intestines, facilitating the movement of contents further along the...
4.3K
Enteral Nutrition I: Orogastric and Nasogastric Feeding
1.9K
Enteral nutrition delivers nutrients directly to the stomach or small intestine through a tube. This method is appropriate for patients who cannot eat but still have a functioning digestive system. It is also beneficial for individuals with swallowing difficulties, anorexia, malabsorption, or those who have undergone gastrointestinal (GI) surgery.
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
Orogastric (OG) and nasogastric (NG) feeding are two standard methods used for enteral nutrition. Enteral nutrition is often preferred over...
1.9K
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
976
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
976

